| |
PDF POSTER
Mitochondrial function, morphology, and metabolic
parameters improve after switching from a
stavudine- to a
tenofovir-containing regimen: SNAP (Switch Nucleoside Analogues Protocol)
C Kim, R Murphy, Berzins, et al
Poster
|
| |
PDF
POSTER
Tolerability of lopinavir/ritonavir liquid in
HIV-positive adults switched from the soft-gel capsule
(SGC) formulation
J Toy, M Harris, J da Silva1, et al
Poster|
|
| |
A WEEK-IN-REVIEW FEATURED REPORT
PDF POSTER
Comparative Assessment of Changes in Blood
Pressure (BP) Through 48-weeks from a Phase 3
Clinical Trial of
Lopinavir/ritonavir (LPV/r)
BA da Silva, M King, RA Rode, et al
Poster |
| |
|
| |
A WEEK-IN-REVIEW FEATURED REPORT
PDF POSTER
Significant improvements in
self-reported gastrointestinal tolerability, quality of life (QoL),
patient
satisfaction, and adherence with lopinavir/ritonavir after
switching from BID soft-gel capsule (SGC)
to BID Tablets
Schrader, SK Chuck, LW Rahn, et al
Poster
|
| |
A WEEK-IN-REVIEW FEATURED REPORT
PDF POSTER
Switching to
lopinavir/ritonavir (LPV/r) Tablets once daily (TAB-QD) from soft-gel
capsule dosed
BID/QD (SGC-BID/SGC-QD) led to significant improvements in
tolerability, diarrhea, antidiarrheal
medication use, and satisfaction
S Schrader,SK Chuck, LW Rahn, et al
Poster |
|
